Driving CARs to BARs: The Winding Road to Specific Regulatory T Cells for Tolerance

David W. Scott*

*Corresponding author for this work

Research output: Contribution to journalReview articlepeer-review

9 Scopus citations


Chimeric antigen receptor (CAR) transduced T cells have significantly improved cancer immunotherapy. Similarly, engineering regulatory T cells (Treg) with specific receptors to endow specificity and increase efficacy of Tregs holds great promise for therapy of a variety of adverse immune responses. In this review, we focus on our approaches using retroviral transduction of specific T-cell receptors, single chain variable fragments (scFv) or antigen in models of monogenic diseases, autoimmunity and allergy. The advantages of each of these for different targets diseases are discussed as well as their potential for clinical translation.

Original languageEnglish
Article number742719
JournalFrontiers in Immunology
StatePublished - 6 Sep 2021
Externally publishedYes


  • EAE (experimental autoimmune encephalitis)
  • allergy
  • autoimmunity
  • chimeric antigen receptor
  • hemophilia
  • regulatory T cell (Treg)
  • tolerance


Dive into the research topics of 'Driving CARs to BARs: The Winding Road to Specific Regulatory T Cells for Tolerance'. Together they form a unique fingerprint.

Cite this